Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.91EUR
2:54pm BST
Change (% chg)

€-0.15 (-7.19%)
Prev Close
€2.06
Open
€2.08
Day's High
€2.08
Day's Low
€1.90
Volume
1,694,012
Avg. Vol
1,303,150
52-wk High
€2.42
52-wk Low
€0.87

Latest Key Developments (Source: Significant Developments)

Pharma Mar H1 Net Result Turns To Loss Of 21.3 Mln Euros
Monday, 29 Jul 2019 

July 29 (Reuters) - Pharma Mar SA ::H1 NET LOSS 21.3 MILLION EUROS VERSUS PROFIT 3.1 MILLION EUROS YEAR AGO.H1 REVENUE 41.4 MILLION EUROS VERSUS 66.4 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar Closes Sale And Transfer Of Its Unit Zelnova Zeltia
Friday, 28 Jun 2019 

June 28 (Reuters) - Pharma Mar SA ::CLOSES SALE AND TRANSFER OF ITS SUBSIDIARY ZELNOVA ZELTIA TO THE COMPANIES ALLENTIA INVEST, S.L. AND SAFOLES, S.A..BUYER PAID PRICE FOR ALL SHARES IN ZELNOVA OF 33.4 MILLION EUROS.  Full Article

Pharma Mar Shareholders Approve Sale Of Zelnova For 33.4 Mln Euros
Wednesday, 26 Jun 2019 

June 26 (Reuters) - Pharma Mar SA ::SHAREHOLDERS APPROVE SALE OF ALL THE SHARES IN ZELNOVA FOR 33.4 MILLION EUROS, ON THE SAME TERMS AS APPROVED BY THE BOARD.  Full Article

Pharma Mar Board Approves Deal For Sale Of Unit Zelnova Zeltia
Thursday, 23 May 2019 

May 23 (Reuters) - Pharma Mar SA ::SAYS BOARD OF DIRECTORS APPROVED SIGNING OF DEAL FOR SALE OF SHARES OF ITS SUBSIDIARY ZELNOVA ZELTIA.TOTAL CONSIDERATION TO BE PAID BY PURCHASER WILL BE 33.4 MILLION EUROS.CLOSING OF TRANSACTION IS INITIALLY EXPECTED TO TAKE PLACE ON JUNE 28, 2019.ESTIMATES DEAL WILL ENTAIL A NET CAPITAL GAIN OF ABOUT 28 MILLION euros IN PHARMA MAR'S INDIVIDUAL ACCOUNTS.UPON CLOSING OF TRANSACTION THIS WOULD ENTAIL LOSS OF ABOUT 2.5 MILLION EUROS IN GROUP'S CONSOLIDATED INCOME STATEMENT.  Full Article

Pharma Mar Q1 Net Loss Widens To 10.5 Mln Euros YoY
Friday, 26 Apr 2019 

April 26 (Reuters) - Pharma Mar SA ::Q1 NET LOSS 10.5 MILLION EUROS VERSUS LOSS 1.3 MILLION EUROS YEAR AGO.Q1 TOTAL REVENUES 19.4 MILLION EUROS VERSUS 27.8 MILLION EUROS YEAR AGO.Q1 NEGATIVE EBITDA 7.1 MILLION EUROS VERSUS NEGATIVE 2.7 MILLION EUROS YEAR AGO.STARTS PROCESS TO DIVEST SUBSIDIARY ZELNOVA, CLASSIFIES ZELNOVA AS ‘AVAILABLE FOR SALE/DISCONTINUED OPERATIONS’.  Full Article

Pharma Mar And Luye Pharma Sign Deal For Development And Sale Of Lurbinectedin In China Territories
Friday, 26 Apr 2019 

April 26 (Reuters) - Pharma Mar SA ::PHARMAMAR AND LUYE PHARMA <<<2186.HK>>> SIGN LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF LURBINECTEDIN IN CHINA TERRITORIES.TO RECEIVE UP-FRONT PAYMENT OF $5 MILLION .OTHER PAYMENTS WILL FOLLOW FOR REGULATORY MILESTONES AND, IN ADDITION, FOR SALES AND ROYALTIES.LUYE PHARMA TO DEVELOP LURBINECTEDIN IN SCLC IN CHINA, WHILE PHARMAMAR TO RETAIN EXCLUSIVE PRODUCTION RIGHTS FOR THE COMPOUND.  Full Article

Pharma Mar FY Net Loss Narrows To 5.5 Mln Euros YoY
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Pharma Mar SA ::FY NET LOSS 5.5 MILLION EUROS VERSUS LOSS 26.7 MILLION EUROS YEAR AGO.FY NET SALES 162.6 MILLION EUROS VERSUS 158.9 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar Receives Approval For Aplidin In Australia
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Pharma Mar SA ::AUSTRALIAN REGULATORY AGENCY (TGA) HAS APPROVED APLIDIN® TO TREAT MULTIPLE MYELOMA IN COMBINATION WITH DEXAMETHASONE.  Full Article

Pharma Mar Says Zepsyre Shows Clinical Activity In Metastatic Breast Cancer With Mutations In Brca 1/2
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Pharma Mar SA ::ZEPSYRE SHOWS SIGNIFICANT CLINICAL ACTIVITY IN METASTATIC BREAST CANCER WITH MUTATIONS IN BRCA 1/2.  Full Article

Pharma Mar 9-Month Net Result Turns To Profit Of 5.0 Mln Euros
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Pharma Mar SA ::9-MONTH NET PROFIT 5.0 MILLION EUROS VERSUS LOSS 14.5 MILLION EUROS YEAR AGO.  Full Article

Spanish stocks - Factors to watch on Monday

MADRID, Aug 19 The following Spanish stocks may be affected by newspaper reports and other factors on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: